68
Views
1
CrossRef citations to date
0
Altmetric
Original Research

LncRNA HLA-F-AS1 Enhances the Migration, Invasion and Apoptosis of Glioblastoma Cells by Targeting lncRNA MEG3

, , &
Pages 9139-9145 | Published online: 11 Dec 2021

References

  • Alexander BM, Cloughesy TF. Adult glioblastoma. J Clin Oncol. 2017;35(21):2402–2409. doi:10.1200/JCO.2017.73.011928640706
  • Holland EC. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A. 2000;97(12):6242–6244. doi:10.1073/pnas.97.12.624210841526
  • Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20(5 Suppl):S2–8. doi:10.1188/16.CJON.S1.2-8
  • Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-Oncology. 2015;17(Suppl4):iv1–iv62. doi:10.1093/neuonc/nov18926511214
  • Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7–13. doi:10.1016/j.jocn.2018.05.00229801989
  • Alifieris C, Trafalis DT. Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther. 2015;152:63–82.25944528
  • Zhang H, Wang R, Yu Y, Liu J, Luo T, Fan F. Glioblastoma treatment modalities besides surgery. J Cancer. 2019;10(20):4793–4806. doi:10.7150/jca.3247531598150
  • Nam JY, de Groot JF. Treatment of glioblastoma. J Oncol Pract. 2017;13(10):629–638. doi:10.1200/JOP.2017.02553629020535
  • Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol. 2017;28(7):1457–1472. doi:10.1093/annonc/mdx10628863449
  • Jain KK. A critical overview of targeted therapies for glioblastoma. Front Oncol. 2018;8:419. doi:10.3389/fonc.2018.0041930374421
  • Le Rhun E, Preusser M, Roth P, et al. Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019;80:101896. doi:10.1016/j.ctrv.2019.10189631541850
  • Duncan CG, Killela PJ, Payne CA, et al. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget. 2010;1(4):265–277. doi:10.18632/oncotarget.13721113414
  • Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21(11):1253–1261. doi:10.1038/nm.398126540387
  • Jiang MC, Ni JJ, Cui WY, Wang BY, Zhuo W. Emerging roles of lncRNA in cancer and therapeutic opportunities. Am J Cancer Res. 2019;9(7):1354–1366.31392074
  • Huang Y, Sun H, Ma X, et al. HLA-F-AS1/miR-330-3p/PFN1 axis promotes colorectal cancer progression. Life Sci. 2020;254:117180. doi:10.1016/j.lfs.2019.11718031863778
  • Wu D, Jia H, Zhang Z, Li S. STAT3-induced HLA-F-AS1 promotes cell proliferation and stemness characteristics in triple negative breast cancer cells by upregulating TRABD. Bioorg Chem. 2021;109:104722. doi:10.1016/j.bioorg.2021.10472233618253
  • Wang X, Li X, Wang Z. lncRNA MEG3 inhibits pituitary tumor development by participating in cell proliferation, apoptosis and EMT processes. Oncol Rep. 2021;45(4). doi:10.3892/or.2021.7991
  • Buccarelli M, Lulli V, Giuliani A, et al. Deregulated expression of the imprinted DLK1-DIO3 region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3. Neuro-Oncology. 2020;22(12):1771–1784. doi:10.1093/neuonc/noaa12732459347
  • Xu DH, Chi GN, Zhao CH, Li DY. Long noncoding RNA MEG3 inhibits proliferation and migration but induces autophagy by regulation of Sirt7 and PI3K/AKT/mTOR pathway in glioma cells. J Cell Biochem. 2018. doi:10.1002/jcb.28026